New hope for rare blood disease: teclistamab trial targets AL amyloidosis

NCT ID NCT06649695

Ongoing Disease control Sponsor: European Myeloma Network B.V. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests a drug called teclistamab in 30 people with AL amyloidosis, a rare disease where abnormal proteins damage organs. Participants have already had other treatments. The goal is to see if teclistamab can reduce or eliminate the harmful proteins in the blood. The study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AL AMYLOIDOSIS

Contacts and locations

Locations

CHU Limoges

Limoges, France
Fondazione I.R.C.C.S Policlinico "San Matteo"

Pavia, Italy
General Hospital of Athens "Alexandra"

Athens, Greece
South Australia Health

Adelaide, Australia
UMC Utrecht

Utrecht, Netherlands
University Hospital Essen

Essen, Germany
University Hospital Heidelberg

Heidelberg, Germany
University Hospital Würzburg

Würzburg, Germany
Westmead Hospital

Sydney, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.